- Fee assured
- Awaiting verification
Professor Middleton trained at the Universities of Cambridge and Oxford, qualifying in 1991. He undertook oncology training at the Christie Hospital and Paterson Institute in Manchester. He has an international reputation for the care of patients with melanoma, participating in numerous clinical trials and contributing to the development of new medicines such as vemurafenib and ipilimumab. Prof Middleton is based at Oxford University Hospitals NHS Trust where he is also responsible for the Early Phase Cancer Trials Unit.
Areas of interest
Treatment of melanoma, including with targeted agents, chemotherapy and immunotherapy. Cancer drug development and experimental therapeutics.
Current NHS consultant posts held
Consultant Medical Oncologist, Oxford University Hospitals NHS Trust.
Melanoma therapeutics and translational research, with a focus on novel immunotherapies and strategies to modulate DNA damage processing.
Early drug development including phase 0 and 1 trials.
Science Translational Medicine, Journal of Clinical Oncology, Cancer Cell, Lancet Oncology.
- BA University of Cambridge 1988
- BM BCh University of Oxford 1991
- MRCP Royal College of Physicians of Edinburgh 1994
- PhD University of Manchester 2000
Professional bodies (positions held - last 3 yrs)
- Executive Member International Melanoma Working Group 2007
Affiliations / memberships
American Association of Cancer Research
American Society of Clinical Oncology